drugset / Trial / NCT00583544
A Safety and Tolerability Single Ascending Dose Study in Healthy Volunteers
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Targacept, Inc. is studying TC-2216 for a potential role in the treatment of central nervous system (CNS) neurobiological disorders in anticipation of seeking an indication in depression and/or anxiety.
Timeline
- Start
- 2007-01
- Primary completion
- 2008-01
- Completion
- 2008-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TC-2216 | Small molecule | — | — |
Indications
No indication recorded.